Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US07373V1052
Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.1 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.15 | |||||
| Beneish M-Score | 0.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1598 | |||||
| 3-Year EBITDA Growth Rate | 9.5 | |||||
| 3-Year EPS without NRI Growth Rate | 15.7 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | 41 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -32.52 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -43.49 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.54 | |||||
| 9-Day RSI | 56.02 | |||||
| 14-Day RSI | 52.24 | |||||
| 6-1 Month Momentum % | 1.21 | |||||
| 12-1 Month Momentum % | -4.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.81 | |||||
| Quick Ratio | 5.81 | |||||
| Cash Ratio | 5.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | -3.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -52.31 | |||||
| Net Margin % | -40.56 | |||||
| FCF Margin % | -43.51 | |||||
| ROE % | -16.48 | |||||
| ROA % | -10.63 | |||||
| ROIC % | -46.19 | |||||
| 3-Year ROIIC % | -28.81 | |||||
| ROC (Joel Greenblatt) % | -78.55 | |||||
| ROCE % | -16.11 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.57 | |||||
| PB Ratio | 2.31 | |||||
| Price-to-Tangible-Book | 2.31 | |||||
| EV-to-EBIT | -6.49 | |||||
| EV-to-Forward-EBIT | -3.76 | |||||
| EV-to-EBITDA | -7.35 | |||||
| EV-to-Forward-EBITDA | -3.36 | |||||
| EV-to-Revenue | 3.4 | |||||
| EV-to-Forward-Revenue | 17.13 | |||||
| EV-to-FCF | -7.59 | |||||
| Price-to-Net-Current-Asset-Value | 3.17 | |||||
| Price-to-Net-Cash | 3.28 | |||||
| Earnings Yield (Greenblatt) % | -15.41 | |||||
| FCF Yield % | -7.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BEAM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beam Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 352.567 | ||
| EPS (TTM) ($) | -1.81 | ||
| Beta | 2.07 | ||
| Volatility % | 94.78 | ||
| 14-Day RSI | 52.24 | ||
| 14-Day ATR ($) | 1.370675 | ||
| 20-Day SMA ($) | 23.5155 | ||
| 12-1 Month Momentum % | -4.41 | ||
| 52-Week Range ($) | 18.8501 - 49.5 | ||
| Shares Outstanding (Mil) | 82.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beam Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beam Therapeutics Inc Frequently Asked Questions
What is Beam Therapeutics Inc(BEAM)'s stock price today?
The current price of BEAM is $23.93. The 52 week high of BEAM is $49.50 and 52 week low is $18.85.
When is next earnings date of Beam Therapeutics Inc(BEAM)?
The next earnings date of Beam Therapeutics Inc(BEAM) is 2024-11-05.
Does Beam Therapeutics Inc(BEAM) pay dividends? If so, how much?
Beam Therapeutics Inc(BEAM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers